Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Application based on clinically meaningful results from the Phase 3 STELLAR trial

News | Cardiovascular Clinical Studies

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

September 28, 2023 — Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a ...

September 28, 2023

Study participants may transition from the rivaroxaban arm to abelacimab in an extension study

News | Cardiovascular Clinical Studies

Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions

September 26, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for ...

September 26, 2023

Feature | TCT

Cardiovascular Research Foundation Preps Program for Scientific Symposium, TCT 2023

September 26, 2023 — The Cardiovascular Research Foundation's (CRF) annual scientific symposium, the Transcatheter ...

September 26, 2023

Videos | Pharmaceuticals

VIDEO, Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

September 26, 2023

Smidt Heart Institute investigators say condition, apparent resistant hypertension, is common, and a particular medication may get patients’ disease under control

News | Hypertension

Novel Study Deepens Knowledge of Treatment-Resistant Hypertension

September 22, 2023 — For many patients with hypertension--an elevated blood pressure that can lead to stroke or heart ...

September 22, 2023

IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients

News | Hypertension

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients

September 20, 2023 — Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to ...

September 20, 2023

News | Heart Valve Technology

Minneapolis Heart Institute Foundation Launches the PROGRESS Clinical Trial to Examine the Safety and Effectiveness of Transcatheter Valve Replacement in Patients with Moderate, Calcific Aortic Stenosis

September 20, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

September 20, 2023

The results of the iHEART project have been published in the prestigious journal 'Nature Scientific Reports'

News | Cardiovascular Clinical Studies

iHEART Simulator, a Mathematical Model of the Heart to Revolutionize Cardiac Research

September 19, 2023 — A mathematical and computational model of the human heart entirely developed at Politecnico di ...

September 19, 2023

Smidt Heart Institute investigators found the rise in illicit substance abuse in pregnancy is associated with significantly high risk of cardiovascular events, maternal mortality

News | Cardiovascular Clinical Studies

Substance Abuse in Pregnancy Doubles Cardiovascular Risk

September 18, 2023 — Pregnant women with a history of substance abuse face a dramatically increased risk of death from ...

September 18, 2023

Study will evaluate the safety and effectiveness of the OMNYPULSE Pulsed Field Ablation (PFA) platform with integrated mapping

News | Cardiovascular Clinical Studies

Biosense Webster Begins Evaluation of Large-tip Focal Pulsed Field Ablation Catheter in Omny-IRE Clinical Trial in Europe

September 18, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

September 18, 2023

Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC

News | Cardiovascular Clinical Studies

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC

September 18, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascu ...

September 18, 2023

First dedicated registry to investigate DCB performance in isolated popliteal artery lesions shows Passeo-18 Lux DCB as beneficial treatment for challenging anatomical segment

News | Drug-Eluting Balloons

BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months

September 14, 2023 — BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry ...

September 14, 2023

Reduced inflammation at the site of myocardial infarction and improved heart function demonstrated. Novel therapy to modulate immune response with apoptotic cell-derived nanovesicles

News | Cardiovascular Clinical Studies

Myocardial Infarction, the Number One Cause of Sudden Death, May be Treated by Modulating the Immune Response

September 14, 2023 — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of ...

September 14, 2023

Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).

News | Cardiovascular Clinical Studies

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of ...

September 12, 2023

Interim results from SOTERIA open-label extension study represent longest safety and efficacy analysis of sotatercept to date

News | Cardiovascular Clinical Studies

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

September 12, 2023